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ABSTRACT
Rationale Criteria for a clinically significant bronchodilator
response (BDR) are mainly based on studies in patients
with obstructive lung diseases. Little is known about the
BDR in healthy general populations, and even less about
the worldwide patterns.
Methods 10 360 adults aged 40 years and older from
14 countries in North America, Europe, Africa and Asia
participated in the Burden of Obstructive Lung Disease
study. Spirometry was used before and after an inhaled
bronchodilator to determine the distribution of the BDR in
population-based samples of healthy non-smokers and
individuals with airflow obstruction.
Results In 3922 healthy never smokers, the weighted
pooled estimate of the 95th percentiles (95% CI) for
bronchodilator response were 284 ml (263 to 305)
absolute change in forced expiratory volume in 1 s from
baseline (DFEV1); 12.0% (11.2% to 12.8%) change
relative to initial value (%DFEV1i); and 10.0% (9.5% to
10.5%) change relative to predicted value (%DFEV1p).
The corresponding mean changes in forced vital capacity
(FVC) were 322ml (271 to 373) absolute change from
baseline (DFVC); 10.5% (8.9% to 12.0%) change relative
to initial value (DFVCi); and 9.2% (7.9% to 10.5%)
change relative to predicted value (DFVCp). The
proportion who exceeded the above threshold values in
the subgroup with spirometrically defined Global Initiative
for Chronic Obstructive Lung Disease (GOLD) stage 2 and
higher (FEV1/FVC <0.7 and FEV1% predicted <80%)
were 11.1%, 30.8% and 12.9% respectively for the
FEV1-based thresholds and 22.6%, 28.6% and 22.1%
respectively for the FVC-based thresholds.
Conclusions The results provide reference values for
bronchodilator responses worldwide that confirm
guideline estimates for a clinically significant level of BDR
in bronchodilator testing.
INTRODUCTION
Airway responsiveness to a bronchodilator is widely
performed in most clinical respiratory function
laboratories throughout the world. Bronchodilator
response (BDR) is used to predict a patient’s
response to bronchodilator treatment, to establish
best attainable lung function, and in clinical trials,
to rule in or rule out asthma and chronic obstruc-
tive pulmonary disease (COPD).1e5 Although
much has been learned about BDR, there continues
to be confusion about its clinical usefulness,6 7 its
pathophysiological basis, its expression8e10 and its
determinants.11
There is also a lack of consensus on the criteria
for a signiﬁcant or increased BDR.12 13 One obstacle
is the lack of agreement on how the response
should be expressed.8e10 12 Another is paucity of
normative reference data derived from healthy
general populations, as has been recommended by
the American Thoracic Society (ATS)12 and the
European Respiratory Society (ERS) guidelines.13
The most common recommendation of a ‘cut-off ’
of 12% change in FEV1 from baseline for signiﬁcant
bronchial responsiveness has been derived from
patients with obstructive lung disease.8 9 14e17 It is
conceivable that these cut-offs may not reﬂect the
spectrum of responsiveness in a healthy general
population.12 To date, the information derived from
general populations is patchy,18e20 and none comes
from non-Western countries. A better under-
standing of the worldwide distribution of BDR in
health and disease would be helpful for developing
global criteria for BDR for clinical use and research.
In this paper we report the BDR in terms of
changes in forced expiratory volume in 1 s (FEV1)
and in forced vital capacity (FVC), measured in
population-based samples from 14 country sites
that participated in the Burden of Obstructive Lung
Disease (BOLD) study.21 22 The focus in this
descriptive report is the distribution of BDR in
healthy populations, with comparison in subpop-
ulations with chronic airway obstruction. From
these, we generated the 95th percentiles and tested
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for variability and consistency across countries and within the
pooled sample from all countries. This study, which drew
participants from countries in North America, Europe, Africa,
and Asia, provided the opportunity for a systematic evaluation
of the reference range of airway response after bronchodilator in
healthy general populations in different regions of the world.
METHODS
Subject design and participants
The target population included women and men aged 40 years
and older in random population samples from 14 countries in
North America, Europe, Africa and Asia. A detailed description
of the study design and rationale, and initial results of the BOLD
study have been published elsewhere.21 22 Population-based
sampling plans were used to recruit participants who were then
invited to complete interviewer-administered standardised
questionnaires on respiratory health and symptoms, smoking
history, quality of life, use of healthcare services, cardiovascular
comorbidities and other respiratory diseases. Pre-bronchodilator
and post-bronchodilator spirometry testing was done for all
eligible participants.
Spirometric testing and quality assurance review
Lung function was obtained at all BOLD sites with the use of
a portable spirometer (EasyOne, ndd Medical Technologies,
Andover, Massachusetts, USA) to collect data on FEV1 and FVC
with forced expiratory time standardised at >6 s or a plateau in
the last second of expiration. With the rare exception in which
spirometry was contraindicated,21 22 all sites attempted to
collect pre- and post-bronchodilator measurements from all
participants. Lung function was measured before and 15 min
after administering two doses of 100 mg of salbutamol (albu-
terol) via a spacer. All spirograms were reviewed by the BOLD
Pulmonary Function Reading Center and assigned a quality score
based on acceptability and repeatability criteria from the ATS.23
Data for FEV1 and FVC were deemed usable and included in this
analysis if they fully met ATS acceptability criteria and were
repeatable to within 200 ml.
Definition of COPD
As in all BOLD publications, we used the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) post-bronchodilator
lung function criteria for deﬁning and staging COPD,21 24 and
the prediction equations for Caucasian derived from the third
US National Health and Nutrition Examination Survey25 to
compute percentage predicted FEV1 and FVC. COPD is deﬁned
as GOLD stage 2 and greater for subgroups computation.
Statistical analysis
Indices of BDR
We generated six measures of BDR, three each for FEV1 and
FVC, using indices recommended by the ATS12 and the ERS10:
Absolute change from baseline values (DFEV1 and DFVC);10 12
percentage change relative to initial value (%DFEV1i and %
DFVCi)10 12; and percentage change relative to predicted value
(%DFEV1p and %DFVCp).8 9 13 18
Establishment of the upper normal limit of BDR
The ‘normal’ range of BDR was determined from its distribution
among healthy never-smoking participants, deﬁned as never
smokers who did not report current asthma, chronic bronchitis,
doctor diagnosis of emphysema, COPD or tuberculosis. The
upper limit of normality of the BDR was deﬁned as the observed
upper 95th percentile18 calculated separately for each site. These
estimates and their associated 95% CIs were then used to
generate forest plots and accompanying weighted estimates of
the 95th percentiles that are pooled across sites along with tests
for heterogeneity across sites. Individual sites are weighted
according to the precision of the estimate at that site and these
weights are reﬂected in the forest plots. We used simple
unweighted statistics to summarise various statistics in tabular
form for the cohort overall and for subgroups. All analyses were
done using Stata V.10.0 (Stata Corp), and the forest plot analyses
used the metan procedure.
RESULTS
Of a total of 10 712 subjects, 10 360 (97%) had either acceptable
pre-bronchodilator and post-bronchodilator FEV1 data
(n¼10 217) or acceptable pre-bronchodilator and post-broncho-
dilator FVC data (n¼9546) and are included in this analysis.
Table 1 shows their demographical and baseline characteristics
by site. The mean ages and SDs ranged from 52.3 (10.3) years in
the Philippines to 60.1 (12.8) years in Norway. Patterns of
current cigarette smoking varied widely across sites: the lowest
smoking rate was 14% in Canada; the highest smoking rate was
46% in South Africa. The intensity of tobacco exposure for
smokers expressed as mean (SD) pack-years ranged from 17.0
(17.4) in South Africa to 38.6 (28.9) in Kentucky, USA.
All indices of BDR in FEV1 and FVC displayed normal or near-
normal distribution for the whole study population. Table 2
shows the simple unweighted estimates of the mean change and
SD of BDR. For the healthy subgroup, these averages were
several fold smaller than the mean values for the subgroup with
COPD. Table 3 shows the simple unweighted estimates of the
upper 95th percentiles (and associated 95% CIs) for the whole
study population and for selected subgroups. BDR, when
expressed as an absolute change, was larger in men than in
women. However the opposite pattern was seen when BDR was
expressed as a percentage change. In addition, per cent change
when expressed relative to initial value was always greater
(sometimes markedly so) when expressed relative to initial
rather than predicted value. Finally, the 95th percentiles were
consistently larger for individuals with COPD (regardless of
comorbid asthma status) than for healthy lifetime never
smokers.
Figures 1e6 show the forest plots of the upper 95th percentile
for the six measures of BDR for the subset of healthy never
smokers. More precise estimates received greater weight, as
shown in the ﬁgures, when calculating the pooled estimates, and
hence the pooled estimates here differ somewhat from the
unweighted estimates of 95th percentiles for all subjects shown
in table 3, although they are qualitatively similar. In healthy
lifetime non-smokers, the pooled weighted estimate of the
threshold for absolute change (DFEV1) is 284 ml, with signiﬁ-
cant cross-site heterogeneity in estimates, that is 54% of overall
variation in estimate comes from site to site variability (ﬁgure 1).
The pooled weighted estimate for %DFEV1p (ﬁgure 3) is smaller
than for %DFEV1i (ﬁgure 2), with no cross-site heterogeneity in
both cases. In contrast, the estimates for the FVC-based
thresholds (ﬁgures 4e6) all demonstrated marked cross-site
heterogeneity, ranging from 66% to 80%.
Using the weighted thresholds from ﬁgures 1e6, we then
calculated the simple, unweighted proportion of individuals who
exceeded these thresholds for various subgroups (table 4). The
proportion of people without airway obstruction who exceeded
the threshold was consistently lower than that for people with
airway obstruction for both the FEV1-based and FVC-based
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thresholds. The proportion of people in the COPD subgroups
who exceeded the FEV1-based thresholds (except for DFEV1i)
decreased with increasing severity of COPD as deﬁned by GOLD
stages.24 By contrast, the proportion of people in the COPD
subgroups who exceeded the FVC-based thresholds showed
a tendency to increase with severity.
DISCUSSION
We measured the BDR in general population samples, aged 40
and older, from sites in 14 countries spanning four continents.
The main ﬁndings indicated that the thresholds or upper limit of
normality for the per cent change in FEV1 relative to initial level
is 12% and for the FEV1 relative to predicted FEV1 is 10%
without heterogeneity across populations. These values agree
well with current ATS guideline cutoffs for deﬁning a signiﬁcant
BDR and strengthen the applicability of these measures for
global interpretation in bronchodilator testing. We further vali-
dated these thresholds in people with and without obstruction
and conﬁrmed that a higher proportion of people with
obstruction of all stages of severity had BDR compared
with those without obstruction, ﬁndings that are consistent
with previous studies in healthy individuals and people with
airway obstruction using ATS-ERS thresholds.10
There were two secondary ﬁndings. First, the BDR threshold
for people with chronic airﬂow obstruction was lower when
asthma was excluded, but there was considerable overlap
between the two groups with and without exclusion of asthma,
consistent with previous studies.1 26 27 Also, there were differ-
ences between the FEV1-based and the FVC-based thresholds in
their association with severity of airﬂow obstruction. The
proportion with reversibility measured by changes in FEV1
generally decreased as COPD severity increased while that with
reversibility measured by changes in FVC increased
with increasing COPD severity, ﬁndings which are consistent
Table 2 Mean and SD (unweighted values) for bronchodilator responses for whole study population, healthy and COPD subgroups
Variables
Study population Healthy subgroup COPD GS2+
COPD GS2+
(without asthma)
All Men Women Men and women Men and women Men and women
FEV1-based measures N1¼10 217 N1¼4826 N1¼5391 N1¼3922 N1¼1009 N1¼745
DFEV1 (ml) 82 (139) 95 (156) 70 (120) 72 (130) 114 (157) 104 (153)
DFEV1i (%) 3.7 (6.9) 3.6 (6.5) 3.8 (7.3) 3.1 (6.0) 8.8 (11.9) 7.7 (11.0)
DFEV1p (%) 2.8 (4.8) 2.7 (4.6) 2.8 (5.0) 2.6 (4.8) 4.2 (5.7) 3.7 (5.5)
FVC-based measures N2¼9546 N2¼4560 N2¼4986 N2¼3593 N2¼976 N2¼723
DFVC (ml) 0 (237) 4 (257) 4 (217) 21 (219) 153 (280) 138 (273)
DFVCi (%) 0.5 (7.9) 0.5 (6.9) 0.5 (8.7) 0.3 (7.4) 6.9 (12.2) 6.2 (11.9)
DFVCp (%) 0.1 (6.6) 0.2 (5.9) 0 (7.3) 0.5 (6.7) 4.4 (7.9) 4.0 (7.6)
DFEV1 (ml) and DFVC (ml) are absolute change after bronchodilator; DFEV1i and DFVCi are change as a per cent of initial value.
DFEV1p and DFVCp are change as per cent of predicted value. N1 is number with non-missing FEV1 values and N2 is number with non-missing FVC values.
COPD GS2+ ¼ FEV1/FVC <0.7 and FEV1% predicted<80%; COPD GS2+ (without asthma) ¼ post-bronchodilator spirometrically defined COPD excluding those with self-reported asthma.
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.
Table 1 Demographics and baseline characteristics of 10 360 participants with usable spirometry data
Australia Austria Canada China Germany Iceland Kentucky Norway Philippines Poland
South
Africa Sweden Turkey UK
N 558 1298 845 572 704 760 517 676 916 562 865 553 846 688
Age (years) 59.0
(12.4)
57.7
(11.6)
56.1
(11.9)
54.0
(10.9)
58.2
(11.0)
56.4
(11.8)
56.7
(9.9)
60.1
(12.8)
52.3
(10.3)
55.8
(11.6)
54.2
(10.4)
58.4
(11.0)
53.7
(10.6)
58.2
(11.5)
Current smoker, % 14.3 19.2 13.5 28.2 20.6 18.3 26.3 26.0 32.4 28.8 45.9 14.7 33.7 21.1
Cigarette exposure
Pack-years
(full cohort)
12.4
(25.4)
13.2
(20.9)
11.9
(23.4)
11.1
(17.9)
15.1
(20.9)
12.8
(24.9)
23.4
(29.3)
12.7
(16.5)
9.7
(17.1)
16.1
(25.3)
11.5
(16.3)
10.5
(16.2)
16.0
(27.0)
16.3
(31.8)
Pack-years
(ever smokers)
24.6
(31.3)
25.3
(23.1)
22.7
(29.1)
26.8
(18.8)
25.1
(21.9)
21.0
(29.1)
38.6
(28.9)
20.1
(16.7)
18.5
(19.8)
26.3
(28.0)
17.0
(17.4)
18.3
(17.7)
29.6
(30.8)
26.3
(36.9)
BMI (kg/m2) 28.0
(5.1)
26.4
(4.2)
26.7
(5.2)
23.2
(3.4)
27.3
(4.6)
27.9
(4.9)
30.7
(6.9)
26.5
(4.3)
24.8
(4.7)
27.6
(4.7)
27.8
(7.4)
27.0
(4.4)
29.5
(5.5)
27.1
(5.0)
Pre-BD FEV1, % pred 93.3
(18.1)
92.8
(17.5)
95.6
(18.4)
84.8
(14.8)
95.2
(17.5)
89.8
(16.4)
83.4
(18.8)
92.3
(16.7)
74.7
(15.4)
92.2
(18.3)
76.8
(19.5)
93.0
(16.1)
89.0
(18.5)
87.6
(17.9)
Post-BD FEV1, % pred 95.9
(17.3)
95.5
(16.7)
99.2
(17.9)
86.5
(14.5)
97.5
(16.9)
93.0
(16.0)
86.7
(18.2)
94.7
(16.5)
77.0
(15.1)
94.9
(17.8)
79.4
(19.0)
95.8
(16.1)
92.3
(17.7)
90.7
(17.3)
GOLD stages*
Stage 1, % 8.3 14.8 10.2 4.3 8.1 8.6 5.4 11.9 1.2 11.6 4.0 9.6 8.6 11.0
Stage 2, % 9.3 8.3 6.3 5.6 5.6 6.7 10.7 7.7 7.1 8.6 13.0 4.7 9.1 9.3
Stage 3, % 1.3 1.1 0.7 1.5 0.7 1.6 3.7 0.9 3.7 1.8 5.8 1.5 1.1 2.1
Stage 4, % 0.0 0.1 0.2 0.2 0.2 0.3 0.2 0.5 0.7 0.0 0.6 0.0 0.4 0.2
Any respiratory medication, % 23.0 6.4 32.4 2.6 19.7 30.0 44.0 13.8 26.5 8.6 9.8 41.6 6.0 22.5
Asthma ever, % 17.2 7.1 14.3 3.2 9.7 16.7 22.1 17.3 6.6 7.3 14.7 14.5 6.4 19.5
Continuous data presented as mean (SD) unless otherwise stated.
*GOLD stage I: FEV1/FVC<70% and FEV1$80% predicted; GOLD stage II: FEV1/FVC<70% and 50%#FEV1<80% predicted; GOLD stage III: FEV1/FVC<70% and 30%#FEV1<50% predicted;
GOLD stage IV: FEV1/FVC<70% and FEV1<30% predicted.
BMI, body mass index; FEV1, forced expiratory volume in 1 s; GOLD, Global Initiative for Chronic Obstructive Lung Disease; FVC, forced vital capacity; Pre-BD FEV1 % pred, pre-bronchodilator
FEV1 % predicted; Post-BD FEV1 % pred, post-bronchodilator FEV1 % predicted.
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with the ﬁndings reported in clinical trials of patients with
COPD, using ATS reversibility criteria.4 These ﬁndings support
the use of lung volume-based measures of reversibility in addi-
tion to FEV1-based measures in patients with more severe
COPD.26
In this analysis the thresholds for BDR for healthy people
were derived from random samples of adults aged 40 years and
over in the general population. According to the ERS guidelines,
an ambiguous BDR should exceed spontaneous variability and
the response observed in healthy individuals.13 Yet, evidence for
the different published criteria had largely been based on data of
selected patients with airﬂow limitation.8 9 14e17 28 Existing data
on the upper limit of the BDR in the healthy population are few
and dated,18 29 although a recent study of unselected urban
population in Iceland reported a 95th percentile of 9% for
increase in FEV1 from baseline (%DFEV1i).19 Therefore, the
results from this study add to reference values from smaller
population studies from single countries18e20 and provided
global reference values for the interpretation of bronchodilator
testing.
Two separate approaches have been used to derive reference
values for a BDR. The ﬁrst method was to assume that values
greater than the 95th percentile in distribution of healthy
subjects was abnormal.18 The second method was to measure
the short-term spontaneous variation or placebo-induced
changes in FEV1 in patients.15e17 The ﬁrst method was used in
this study. The joint ATS-ERS guidelines10 recommendation of
12% percentage change from baseline and 200 ml absolute
changes in FEV1 and/or FVC in an individual subject to identify
a positive/signiﬁcant BDR was derived using the second
approach, but recognised the need to obtain references in
healthy populations based on the ﬁrst method. Thus, the results
Figure 1 Absolute change in forced
expiratory volume in 1 s (FEV1) in ml
after bronchodilator (DFEV1) expressed
as 95th percentile with 95% CI in
healthy non-smokers. Those sites
whose estimates are most stable get
greater weight (right-hand column) in
constructing the pooled estimate of
284 ml. We observed significant
heterogeneity across sites (p¼0.008),
with 54% of the overall variability in the
data attributable to siteesite variability.
Table 3 Upper 95th percentiles with 95% CI (unweighted values) for bronchodilator responses for whole study population, healthy and COPD
subgroups
Variables
Study population Healthy Subgroup COPD GS2+
COPD GS2+
(without asthma)
All Men Women Men and women Men and women Men and women
FEV1-based measures N1¼10 217 N1¼4826 N1¼5391 N1¼3922 N1¼1009 N1¼745
DFEV1 (ml) 314 (306 to 324) 354 (340 to 368) 265 (257 to 278) 291 (279 to 309) 371 (343 to 402) 341 (323 to 381)
DFEV1i (%) 14.6 (14.1 to 15.3) 14.0 (13.2 to 14.6) 15.4 (14.5 to 16.0) 12.5 (11.9 to 13.2) 30.9 (27.8 to 33.8) 27.7 (21.6 to 30.9)
DFEV1p (%) 10.6 (10.3 to 10.9) 10.2 (9.9 to 10.6) 10.9 (10.5 to 11.3) 10.1 (9.7 to 10.7) 13.1 (12.3 to 14.6) 12.3 (11.6 to 13.5)
FVC-based measures N2¼9546 N2¼4560 N2¼4986 N2¼3593 N2¼976 N2¼723
DFVC (ml) 395 (381 to 414) 454 (419 to 486) 347 (328 to 374) 337 (317 to 358) 635 (591 to 678) 619 (547 to 668)
DFVCi (%) 13.3 (12.7 to 13.9) 12.6 (11.8 to 13.4) 14.1 (13.2 to 15.1) 11.2 (10.5 to 12.2) 29.4 (26.6 to 31.6) 26.7 (24.4 to 30.6)
DFVCp (%) 10.8 (10.4 to 11.4) 10.4 (9.7 to 10.8) 11.6 (10.7 to 12.5) 9.6 (9.1 to 10.3) 18.0 (17.0 to 19.7) 17.3 (15.7 to 18.8)
DFEV1 (ml) and DFVC (ml) are absolute change after bronchodilator; DFEV1i and DFVCi are change as a per cent of initial value; DFEV1p and DFVCp are change as per cent of predicted value.
N1 is number with non-missing FEV1 values and N2 is number with non-missing FVC values.
COPD GS2+ ¼ FEV1/FVC <0.7 and FEV1% predicted<80%; COPD GS2+, without asthma ¼ COPD GS2+ but with no self-reported diagnosis of asthma.
In the COPD subgroups, the CIs for individual sites were large due to small sample size (<50).
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.
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from this study provided new data relevant to this gap in
information.
The ‘cutoff ’ values in our analysis differ somewhat compared
with those from single site population studies of healthy
subjects. For deﬁning a positive response, these studies had
suggested 95th percentile thresholds of 130 ml18 or 240 ml19 for
absolute change in FEV1; 9%18 or 5.9%19 for percentage change
in FEV1 from initial value (%ΔFEV1i) and 9%8 18 for change in
FEV1 relative to predicted value (%ΔFEV1p). In our study, the
derived cutoffs for %ΔFEV1i and %ΔFEV1p are higher but stable
as evidenced by the lack of site heterogeneity. Also, these
threshold values complied with the caution to exceed the
measurement variability of at least 8% change within individ-
uals for deﬁning an unambiguous response.8 30 31 The FVC
Figure 3 Percentage change in forced
expiratory volume in 1 s (FEV1) relative
to predicted FEV1, after bronchodilator
(%DFEV1p) expressed as 95th percentile
with 95% CI in healthy non-smokers.
The pooled estimate is 10% with no
evidence of cross-site heterogeneity.
Figure 2 Percentage change in forced
expiratory volume in 1 s (FEV1) relative
to initial baseline, after bronchodilator
(BDR FEV1i) expressed as 95th
percentile with 95% CI in healthy non-
smokers. The pooled estimate is 12%
with no evidence of cross-site
heterogeneity.
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thresholds were included as the ATS-ERS recommendation
included these10 to accommodate ﬂow responders and volume
responders to inhaled bronchodilators.32 33 However, it is worth
noting that the issue of heterogeneity is much more a concern
for FVC than for FEV1, at least so long as the latter is expressed
as a per cent change of initial or predicted value.
Comparison of our healthy population-based thresholds with
the thresholds of guidelines based on patient studies provided
insight into the short-term variability of BDR measurements. In
this global study, the 95th percentile cutoffs of BDR in healthy
never smokers of 12% for DFEV1i was identical to the cutoffs of
12% change in FEV1 or FVC for a positive response required by
international guidelines,10 while 10% for DFEV1p was similar to
the 9% change found by one study.8 The guideline recommen-
dation for a positive BDR had been based on observations in
selected patients with asthma and COPD, and on the fact that
Figure 5 Percentage change in forced
vital capacity (FVC) relative to initial
baseline, after bronchodilator (BDR
FVC1i) expressed as 95th percentile
with 95% CI in healthy non-smokers.
Those sites whose estimates are most
stable get greater weight (right-hand
column) in constructing the pooled
estimate of 11%. We observed
significant heterogeneity across sites
(p<0.0001), with 66% of the overall
variability in the data attributable to
siteesite variability.
Figure 4 Absolute change in forced
vital capacity (FVC) after bronchodilator
(BDR FVC, ml) expressed as 95th
percentile with 95% CI in healthy non-
smokers. Those sites whose estimates
are most stable get greater weight
(right-hand column) in constructing the
pooled estimate of 322 ml. We
observed significant heterogeneity
across sites (p<0.0001), with 75% of
the overall variability in the data
attributable to siteesite variability.
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there was a short-term intra-subject variability of 200 ml in ﬂow
volume indices.34 Although the long-term variability in lung
function in patients is larger than in healthy subjects, the short-
term variability in patients in a stable condition is very similar to
normal subjects, with an observed 95% CI of change in FEV1 of
190 ml and 12.3%.15 16 This could be a potential explanation for
the similarity between threshold values in our study and the
guideline recommendations.10
There is no consensus on how BDR is best expressed: in
absolute terms or as percentage of the initial value,10 12 or as
percentage of predicted value.13 Of the six indices of BDR in this
global study, we showed that the percentage change in FEV1
relative to either baseline or predicted were the most stable
across sites, while there was signiﬁcant site-to-site variability in
all FVC estimates and in absolute FEV1 change. Overall, this
population-based evidence supports the use of 10% increase
relative to predicted FEV1 to determine bronchodilator revers-
ibility, as this feature is stable across sites, is independent of sex
and stable across GOLD stages, yet discriminates healthy
subjects from obstructive individuals. Nevertheless, in practice,
it would be prudent to couple any percentage threshold with
a qualifying volume threshold.10
This is the ﬁrst study to compare BDR in population-based
samples from a large number of sites on several continents. This
information adds to the growing body of data on lung function
that will help us to understand the range of normality and what
may inﬂuence this. Other strengths of the study include the
careful attention to standardisation and quality control used
across all sites in the BOLD study21 22 and the well recognised
technique of deﬁning the 95th percentile in the healthy popu-
lation for deriving the reference for BDR thresholds.18 19 In
addition, the analysis of FVC data using different criteria is
much more comprehensive than in other reports.6
A potential limitation of the study is that our deﬁnition of
healthy never smokers relies on self-report of doctor-diagnosed
lung disorders rather than objectively deﬁned obstructive lung
Table 4 The proportion of people in excess of thresholds for overall cohort, for subgroups of normal, GOLD stage 1, GOLD stage 2 and GOLD stage
3e4
Variables Overall Normal GOLD stage 1 GOLD stage 2 GOLD stage 3e4
FEV1-based thresholds N1¼10 217 N1¼7931 N1¼846 N1¼790 N1¼219
DFEV1 (>284 ml) 6.7% 5.6% 11.5% 12.2% 7.3%
DFEV1i (>12%) 7.8% 4.4% 11.6% 27.3% 43.4%
DFEV1p (>10%) 6.0% 4.3% 12.3% 13.9% 9.1%
FVC-based thresholds N2¼9546 N2¼7697 N2¼819 N2¼764 N2¼212
DFVC (>322 ml) 7.5% 4.0% 21.2% 20.7% 29.7%
DFVCi (>10.5%) 7.5% 3.8% 17.0% 24.7% 42.5%
DFVCp (>9.2%) 6.8% 3.2% 21.6% 20.5% 27.8%
DFEV1 (ml) and DFVC (ml) are absolute change after bronchodilator; DFEV1i and DFVCi are change as a per cent of initial value; DFEV1p and DFVCp are change as per cent of predicted value.
N1 is number with non-missing FEV1 values and N2 is number with non-missing FVC values.
Normal ¼ not classified as any GOLD stage; GOLD stage 1 ¼ FEV1/FVC <0.7 and FEV1 % predicted >80%; GOLD stage 2 ¼ FEV1/FVC <0.7 and FEV1 % predicted <80% and >50%; GOLD
stage 3e4 ¼ FEV1/FVC <0.7 and FEV1 % predicted <50%.
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease.
Figure 6 Percentage change in forced
vital capacity (FVC) relative to predicted
FVC, after bronchodilator (BDR FVCp)
expressed as 95th percentile with 95%
CI in healthy non-smokers. Those sites
whose estimates are most stable get
greater weight (right-hand column) in
constructing the pooled estimate of 9%.
We observed significant heterogeneity
across sites (p<0.0001), with 80% of
the overall variability in the data
attributable to siteesite variability.
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disease, since both diagnostic practices and access to care might
vary across our widely dispersed sites. Nonetheless this is stan-
dard practice for developing reference equations for lung func-
tion.25 Also, we would note that only 4% of our healthy never
smokers met criteria for GOLD stage 2 or higher COPD,
suggesting that the results would be unlikely to change much by
excluding these individuals, and indeed we conﬁrmed this
for tables 2 and 3 (data not shown). Second, because the
distribution of BDRs are continuous and unimodal as had been
shown in clinical studies8 9 15 and population studies,18e20 the
cutoff value for a ‘positive’ response in all studies, including
ours, remained somewhat arbitrary.35 Third, we used 200 mg of
salbutamol/albuterol instead of higher doses as an extra
precaution because it was a ﬁeld study and involved home visits
in many sites. While GOLD guidelines recommended 400 mg,
many published clinical studies have used different types and
doses of drugs as summarised in the recent paper on broncho-
dilator reversibility by Hanania et al.26 Lastly, we demonstrated
the effect of acute reversibility due to bronchodilator in one
setting but not its reproducibility on repeated testing and also
not the long-term reversibility due to anti-inﬂammatory drugs.
Hence, a lack of a response to bronchodilator testing in one
setting may not preclude a clinical response to bronchodilating
or anti-inﬂammatory therapy.10 24
In conclusion, the results from this study add new worldwide
data on the distribution of bronchodilator response and airway
reversibility. The reference values derived from healthy individ-
uals addressed the reference gap in BDR. The values agreed well
with the current guideline cutoffs for a signiﬁcant BDR, were
discriminative for different subpopulations and strengthen the
applicability of these measures for global interpretation in
bronchodilator testing.
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